Velibor Krstic Reports New 8.3% Stake in Strata Critical Medical Warrants

Velibor Krstic, a private investor based in Switzerland, filed a Schedule 13D on April 7, 2026, reporting the acquisition of 764,435 warrants of Strata Critical Medical, Inc. (SRTA). This position represents approximately 8.3% of the outstanding public warrants. The acquisitions were made through open market transactions on the Nasdaq for a total purchase price of approximately $15,231 using personal funds. Krstic believes the warrants are significantly undervalued relative to the company's fundamentals, citing an Adjusted EBITDA of $14.1 million and the integration of Keystone Perfusion. With the warrants set to expire on May 7, 2026, Krstic intends to actively monitor management and may engage in discussions with the Issuer and its sponsor, KSL Capital Partners. These discussions may involve exploring options to maximize investment value, such as a voluntary exchange offer or amendments to the warrant agreement. This filing marks a new 5% beneficial ownership stake for the reporting person.